9MW2821-2023-CP301, CTR20234024: A randomized, open-label, controlled, multicenter phase III clinical study of 9MW2821 versus investigator-selected chemotherapy for the treatment of unresectable locally advanced or metastatic urothelial carcinoma previously treated with platinum-containi |
|
|
| Not yet recruiting | 3 | 420 | China | 9MW2821 - Mabwell (Shanghai) Biosci, docetaxel - Generic mfg., paclitaxel - Generic mfg. | Jiangsu Maweikang New Drug R&D Co., Ltd | Urothelial carcinoma | | | | |
NCT06196736: A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Not yet recruiting | 3 | 420 | RoW | 9MW2821, Chemotherapy | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/28 | | |
